Discover public health benefits of quadrivalent live attenuated influenza vaccines, as presented by Filip Dubovsky, Vice Presideent Clinical Development, Therapeutic Area Head, Vaccines, MedImmune, United States.
Dr. Filip Dubovsky joined MedImmune in August 2006 as director, clinical development and was named vicee president, clinical development, and global clinical therapeutic head, vaccines in July 2008. In this capacity, he leads the vaccine clinical development programs and the vaccine clinical activities for MedImmune’s influenza franchise.
Prior to joining MedImmune, Dr Dubovsky held several roles of increasing responsibility in support of the Malaria Vaccine Initiative, PATH, including creating, managing and defending a portfolio of 25 malaria vaccine candidates spanning from early candidate optimization to Phase 3 clinical trial presentation. He also previously served in a clinical capacity at Stanford University, University of Maryland and John’s Hopkins University hospitals.
At the World Influenza Congress Asia Summit 2011, Dr. Filip Dubovsky presented on the following:
1. Understanding the significant morbidity and mortality around the world caused by distinct Influenza B lineages
2. Evaluating the protection level of trivalent influenza vaccines containing B-strain from a single lineage
3. Addressing public health problems with the development of quadrivalent live attenuated influenza vaccine containing both B lineages.
To find out more about what Filip Dubovsky, Vice Presideent Clinical Development, Therapeutic Area Head, Vaccines, MedImmune, United States had to say, click here to download his slides now!